Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Avapritinib Leads a Charge of Novel Targeted Therapies for Indolent Systemic Mastocytosis

March 19th 2025

Tsewang Tashi, MD, discusses the efficacy and tolerability of targeted therapies like avapritinib for patients with indolent systemic mastocytosis.

Brentuximab Vedotin Combo Adds Another Targeted Option Beyond CD19/CD20 in R/R LBCL

March 19th 2025

Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma

March 19th 2025

The FDA approved pembrolizumab, trastuzumab, and chemotherapy for HER2-positive, PD-L1–positive gastric/GEJ adenocarcinoma.

Association Between CLDN18 and MUC1 Could Drive Novel Targeted Therapy Options in GI Cancers

March 19th 2025

Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

March 18th 2025

Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

QuANTUM-Wild Trial to Explore Correlative Outcomes With Quizartinib in FLT3-Negative AML

March 18th 2025

David M. Swoboda, MD, discusses data with quizartinib in FLT3-negative AML from the QUIWI trial and the rationale for the QuANTUM-Wild trial.

Dr Rampal on ​Emerging Therapies Under Investigation in Myelofibrosis

March 17th 2025

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer

March 17th 2025

The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.

Durvalumab Secures EU Approval for LS-SCLC After CRT

March 17th 2025

The European Commission approved durvalumab for limited-stage small cell lung cancer without disease progression following chemoradiation.

Orca-T Improves cGVHD-Free Survival in Advanced Hematologic Malignancies

March 17th 2025

Orca-T led to an improvement in chronic graft-vs-host disease–free survival in patients with advanced hematologic malignancies.

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer

March 16th 2025

Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer With Low/Medium FRα Expression

March 16th 2025

Luveltamab tazevibulin was active and safe in patients with platinum-resistant ovarian cancer and a FRα expression of at least 25%.

7-Year Data Show Feasibility of Elective Treatment Interruption of Venetoclax/Ibrutinib in R/R MCL

March 14th 2025

Patients with relapsed/refractory MCL who opted for elective treatment interruptions from venetoclax/ibrutinib experienced durable responses.

Liso-Cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma

March 14th 2025

The European Commission has approved liso-cel in relapsed/refractory follicular lymphoma after at least 2 prior lines of systemic therapy.

D-MNA Displays Potential as Noninvasive Therapy in Basal Cell Carcinoma of the Skin

March 14th 2025

Micro-array needles containing doxorubicin displayed safety and early activity in basal cell carcinoma of the skin.

AVA6000 Generates Early Efficacy, Is Safe in Advanced Salivary Gland Cancers

March 14th 2025

AVA6000 showed early efficacy and safety signals in previously treated, locally advanced or metastatic salivary gland cancers.

Pembrolizumab Produces Durable Responses in Chemo-Pretreated Clear Cell Gynecologic Cancers

March 13th 2025

Treatment with pembrolizumab monotherapy was effective and well tolerated in pretreated patients with advanced clear cell gynecologic cancers.

Dr DeAngelo on the Efficacy of Avapritinib in Advanced Systemic Mastocytosis

March 13th 2025

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

Palbociclib/Letrozole Combo Boosts PFS in ER+ Advanced/Recurrent Endometrial Cancer

March 13th 2025

Palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole in patients with ER-positive advanced endometrial cancer.

FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases in Lung Cancer

March 12th 2025

The FDA granted orphan drug designation to rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from lung cancer.

NEXT PAGE
PREVIOUS PAGE
x